https://www.selleckchem.com/pr....oducts/beta-lapachon
The arrival of immunotherapies and targeted therapies challenged the authorities to make them available as soon as possible. France has effective tools, such as clinical trials (CTs) and a national early access program (temporary authorizations for use [ATUs] and temporary recommendations for use [RTUs]), allowing the use of innovative drugs, whether or not they have been authorized or used off-label, for cases that have reached a therapeutic impasse. The methodology involved real-time data collection from ATUs, RTUs (between Sep
Like
Comment
Share
